Showing 5953–5968 of 7559 results

Ruxolitinib (INCB018424)

Ruxolitinib (INCB018424) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays, >130-fold selectivity for JAK1/2 versus JAK3.

Drospirenone

Drospirenone is a synthetic progestin that is an analog to spironolactone.

Gestodene

Gestodene is a progestogen hormonal contraceptive.

Dorzolamide HCl

Dorzolamide HCl is a water-soluble, potent inhibitor of human carbonic anhydrase II and IV with Ki of 1.9 nM and 31 nM, respectively, used as anti-glaucoma agent.

Doripenem Hydrate

Doripenem Hydrate is an ultra-broad-spectrum injectable antibiotic, used to treat complicated intra-abdominal infections and complicated urinary tract infections.

Daptomycin

Daptomycin is a novel antibiotic with rapid in vitro bactericidal activity against gram-positive organisms.

Biapenem

Biapenem is a carbapenem antibiotic with activity against both Gram-positive and Gram-negative bacterial strains.

Bafetinib (INNO-406)

Bafetinib (INNO-406) is a potent and selective dual Bcr-Abl/Lyn inhibitor with IC50 of 5.8 nM/19 nM in cell-free assays, does not inhibit the phosphorylation of the T315I mutant and is less potent to PDGFR and c-Kit. Phase 2.

Acitretin

Acitretin is a second generation retinoid used for psoriasis.

Amonafide

Amonafide produces protein-associated DNA-strand breaks through a topoisomerase II-mediated reaction, but does not produce topoisomerase I-mediated DNA cleavage. Phase 3.

BMS-707035

BMS-707035 is a specific HIV-I integrase (IN) inhibitor with IC50 of 15 nM. Phase 2.

Ki8751

Ki8751 is a potent and selective inhibitor of VEGFR2 with IC50 of 0.9 nM, >40-fold selective for VEGFR2 than c-Kit, PDGFRα and FGFR-2, little activity to EGFR, HGFR and InsR.

Rigosertib (ON-01910)

Rigosertib (ON-01910) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM in a cell-free assay. It shows 30-fold greater selectivity against Plk2 and no activity to Plk3. Phase 3.

MGCD-265 Analog

Glesatinib (MGCD265) is a potent, multi-target and ATP-competitive inhibitor of c-Met and VEGFR1/2/3 with IC50 of 1 nM, 3 nM/3 nM/4 nM, respectively also inhibits Ron and Tie2. Phase 1/2.